Atreca, IGM and BeiGene Partner to Develop Novel SARS-CoV-2 Treatment
May 01, 2020 at 07:08 AM EDT
Atreca, IGM Biosciences and BeiGene formed a three-way collaboration to discover and develop engineered immunoglobulin IgM and IgA antibodies targeting SARS-CoV-2. BeiGene will support clinical development of the product using its global clinical trial team. To speed development, the companies not established the financial terms of the agreement, leaving that task until later. They hope to have a candidate ready to begin clinical testing in the first half of 2021. Atreca is located in South San Francisco, IGM in Mountain View, California, and BeiGene in Beijing. More details.... Stock Symbols: (NSDQ: BCEL) (NSDQ: IGMS) (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //
